ARTICLE SUMMARY:
Point-of-care testing (POCT) is one of the fastest growing segments of the diagnostics market, as consumers and physicians are eager for rapid, cost-effective information that cuts the traditional wait time for test results and speeds up clinical decision making. In emerging markets, the need is more intense as many regions do not have consistent, timely access to central laboratories.
Current interest is especially strong for molecular testing, a factor which led earlier this year to Abbott Laboratories’ $5.8 billion bid for Alere Inc.
